Avenue Therapeutics, Inc. Common Stock (ATXI)

ATXI was delisted on the 18th of March, 2025.

• Market cap: $863K
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Employees: 3